NewNow you can hear Fox News article!
Some patients taking GLP-1 drugs for weight loss have been forced to switch to a separate drug due to changes in insurance coverage-and they are not happy about it.
By 1 July, CVS Caremark – One of the largest pharmacy profit managers in the US – dropped Zepbound (Tirzepetide) from his favorite drug list, replaced it with Vagovi (Semglutide).
Zepbound – With its counterpart diabetic drug, is created by Mounjaro – Elli Lily, while the vegovi is produced by Novo Nordisk, which also makes ozmpic.
CVS Cayermark drops popular weight loss coverage coverage
CVS Cayermark blamed the rising costs for change. In a statement of June 27 on its website, the company said that “drug manufacturers are completely responsible for setting the price of drugs and the price of these drugs is done at high cost, making it difficult for many people to access them.”
“Attempts to reduce the price of low out-off-pocket drugs,” CVS Caremark said she participated with Novo Nordisk, “increased access to Wegovi for our members at a more cheap price for our members.”
Some patients taking GLP-1 drugs for weight loss have been forced to switch to a separate drug due to changes in insurance coverage. (Istock)
“On July 1, 2025, we will take a formulator to like Vegovi and remove Zepbound,” the statement continued. “We are confident that our decision to like Vagovi on our commercial template formulaies will enable weight management drugs, comprehensive, more affordable coverage, while preserving clinical integrity.”
Dr, a board-prohibited doctor who practiced internal and obesity medicine located in New York. Tro Kalayajian said that the lack of patients’ choice always affects patients negatively.
The study shows the primary cause of obesity – and it is not a lack of exercise
“Some people do not tolerate some drugs, and are forced to convert into a new drug, which presents a clear avenue for progress,” he told Fox News Digital. “Forced switching disrupts the continuity of care.”
“Switching drugs is not always uninterrupted; the dose should often be seen again, and side effects can emerge again.”
Wegovy is an injected prescription weight-loss drug created by Danish company Novo Nordisk. (Michael Siluk/UCG/Universal Image Group Getty Image)
Many patients receiving letters from the cairmark about the switch have been taken on social media to express their concerns.
One user wrote on Reddit, “I was approved for Zepbound two months ago … I am only on this for two months and I am already 25.8 pounds below.” “I have extended my dose twice because I am now in three months, and I have no side effects. It’s working so well for me, I am really nervous about changing medicines.”
Popular weight loss drugs promise new power against weak migraine
Another user wrote, “CVS sent just a letter stating that it was no longer covered and I could infection in Vagovi. However, I tried Vagovi before Jeepbound and made me completely sick. This rule should be exception. Since I am using only every other week.
“It’s working so well for me, I am really nervous about switching medicines.”
CVS Caremark said in its announcement that the patients first tried Vagovi and
Expercried “serious or unbearable
“You or your provider can begin an exception request, which allows a case-by-case medical requirement to determine whether the coverage for alternative medicine is suitable based on your clinical conditions,” the company said.
Zepbound – Its equivalent is made by Mounjaro – Eli Lily, headquartered in Indianapolis, with diabetes drug. (Istock)
Patients can choose to buy Zepbound directly from Ellie Lily, said Kalayjian, but the drug is expensive, which costs around $ 300- $ 500 per month.
“Unfortunately, people are so frustrated that they are buying research-grade versions of drugs from Tiktok and social media,” he warned.
Click here to get Fox News app
Kalyzian stated that the Jeepbound is “slightly more effective” than Vagovi, as it has an additional mechanism, but both drugs are “very similar” in their weight loss consequences.
“There is a little less nausea and vomiting with zepbound,” he said.
A recent study found that the tirzepetide lost overweight than semaglutide, the participants shed around 50 pounds (20.2%of their body weight). (Istock)
In a 72-week clinical trial published in the New England Journal of Medicine, researchers compared the safety and efficacy of Tirzepetide (Zepbound) and Semaglutide (vegovi).
Click here to sign up for our health newspaper
The study found that Tirzepatide achieved Overweight lossThe participants shed around 50 pounds (20.2%of their body weight).
The semaglutide -taking group lost average of 33 pounds or 13.7% on an average according to a press release summarizing the result of the study.
“It is not always comfortable to switch drugs; the dose should often be tightened again, and side effects can emerge again,” said an expert. (Istock)
Overall, 32% of people lost tirizeptide people lost at least 25% of their body weight; Semaglutide users lost about 16%.
Tirzepatide users also reported “more reduction in waist circumference” on semaglutide than those.
For more health articles, travel www.foxnews.com/health
Reported side effects were very similar for two drugs, with 44% of people experience nausea and 25% stomach ache.
Fox News approached Eli Lily and Novo Nordisk for digital comment.
